Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Third Survey of Prescription Pattern of Psychotropic Drugs in China

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01668810
Recruitment Status : Unknown
Verified July 2012 by Si Tianmei, Peking University.
Recruitment status was:  Recruiting
First Posted : August 20, 2012
Last Update Posted : August 20, 2012
Sponsor:
Collaborator:
Xian-Janssen Pharmaceutical Ltd.
Information provided by (Responsible Party):
Si Tianmei, Peking University

Tracking Information
First Submitted Date August 16, 2012
First Posted Date August 20, 2012
Last Update Posted Date August 20, 2012
Study Start Date July 2012
Estimated Primary Completion Date September 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Third Survey of Prescription Pattern of Psychotropic Drugs in China
Official Title The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder
Brief Summary The investigators aimed to examine the psychotropic prescription pattern in China.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Ecologic or Community
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population schizophrenia, depression and bipolar disorder patients
Condition Prescription
Intervention Not Provided
Study Groups/Cohorts
  • Beijing region
    include six hospitals
  • Guangdong Province
    include 3 hospitals
  • Jiangsu province
    include 3 hospitals
  • Hebei province
    include 6 hospitals
  • Hubei Province
    include 7 hospitals
  • Shanxi province
    include 3 hospitals
  • Jiangxi province
    include 3 hospitals
  • Jilin province
    include 6 hospitals
  • Sichuan province
    include 3 hospitals
  • Shaanxi province
    include 3 hospitals
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: August¬†17,¬†2012)
7000
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2013
Estimated Primary Completion Date September 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65

-

Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries China
Removed Location Countries  
 
Administrative Information
NCT Number NCT01668810
Other Study ID Numbers RISSCH4255
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Si Tianmei, Peking University
Study Sponsor Peking University
Collaborators Xian-Janssen Pharmaceutical Ltd.
Investigators
Study Chair: Xin Yu, MD. Peking University
PRS Account Peking University
Verification Date July 2012